
Imegli500 mg
ACME Laboratories Ltd.
Imeglimin Hydrochloride is indicated for the management of type 2 diabetes mellitus (T2DM) in adults, used to improve glycemic control alongside diet and exercise.
Imeglimin Hydrochloride is indicated for the management of type 2 diabetes mellitus (T2DM) in adults, used to improve glycemic control alongside diet and exercise.
Imeglimin Hydrochloride belongs to a relatively new therapeutic class, and its place in overall diabetes treatment algorithms is still evolving as more clinical experience accumulates. It is not indicated for type 1 diabetes or diabetic ketoacidosis.
Dosing of Imeglimin Hydrochloride should always be individualized by the prescribing physician based on glycemic response and tolerability.
| Indication | Typical Adult Dosage |
|---|---|
| Type 2 diabetes mellitus (monotherapy or combination) | 1000 mg taken orally twice daily (morning and evening), with or without food, as advised by the physician |
Renal impairment: Not recommended in patients with severe renal impairment (see Contraindications); dose adjustment or physician review is advised in mild-to-moderate renal impairment.
Hepatic impairment: Use with caution and under close physician supervision in patients with hepatic impairment, given limited data.
Pediatric use: Safety and efficacy have not been established in children (see Use in Special Populations).
Reported adverse effects with Imeglimin Hydrochloride include:
Patients should report persistent gastrointestinal symptoms, unusual muscle pain, breathing difficulty, or unexplained fatigue promptly to their physician.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.